Literature DB >> 29362786

Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications.

Steven Woloshin1, Lisa M Schwartz1, Pamela J Bagley2, Heather B Blunt2, Brian White3.   

Abstract

Mesh：

Year:  2018        PMID： 29362786      PMCID： PMC5833570          DOI： 10.1001/jama.2017.20653

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.

Authors:  Andreas L Petzer; Dominic Fong; Thomas Lion; Irina Dyagil; Zvenyslava Masliak; Andrija Bogdanovic; Laimonas Griskevicius; Sandra Lejniece; Stefan Goranov; Liana Gercheva; Aleksandar Stojanovic; Dontcho Peytchev; Nikolay Tzvetkov; Rasa Griniute; Atanas Stanchev; Thomas Grubinger; Marthin Kwakkelstein; Peter Schuld; Guenther Gastl; Dominik Wolf
Journal:  Haematologica       Date:  2012-04-17       Impact factor: 9.941

Review 2.  Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.

Authors:  Dirk Bassler; Matthias Briel; Victor M Montori; Melanie Lane; Paul Glasziou; Qi Zhou; Diane Heels-Ansdell; Stephen D Walter; Gordon H Guyatt; David N Flynn; Mohamed B Elamin; Mohammad Hassan Murad; Nisrin O Abu Elnour; Julianna F Lampropulos; Amit Sood; Rebecca J Mullan; Patricia J Erwin; Clare R Bankhead; Rafael Perera; Carolina Ruiz Culebro; John J You; Sohail M Mulla; Jagdeep Kaur; Kara A Nerenberg; Holger Schünemann; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Heiner C Bucher; Alain J Nordmann; Heike Raatz; Suzana Alves da Silva; Fabio Tuche; Brigitte Strahm; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Paul J Karanicolas; Karen E A Burns; Per Olav Vandvik; Fernando Coto-Yglesias; Pedro Paulo M Chrispim; Tim Ramsay
Journal:  JAMA       Date:  2010-03-24       Impact factor: 56.272

3.  Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.

Authors:  Hao Wang; Gary L Rosner; Steven N Goodman
Journal:  Clin Trials       Date:  2016-06-07       Impact factor: 2.486

Review 4.  Publishing interim results of randomised clinical trials in peer-reviewed journals.

Authors:  Nicholas Counsell; Despina Biri; Joanna Fraczek; Allan Hackshaw
Journal:  Clin Trials       Date:  2016-11-26       Impact factor: 2.486

5.  High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

Authors:  Andreas L Petzer; Dominik Wolf; Dominic Fong; Thomas Lion; Irina Dyagil; Zvenyslava Masliak; Andrija Bogdanovic; Laimonas Griskevicius; Sandra Lejniece; Stefan Goranov; Liana Gercheva; Aleksandar Stojanovic; Dontcho Peytchev; Nikolay Tzvetkov; Rasa Griniute; Radka Oucheva; Hanno Ulmer; Marthin Kwakkelstein; Francesca Rancati; Guenther Gastl
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 6.  Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential?

Authors:  R J Stephens; R E Langley; P Mulvenna; M Nankivell; A Vail; M K B Parmar
Journal:  Lung Cancer       Date:  2014-05-22       Impact factor: 5.705
  6 in total
  4 in total

1.  Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual.

Authors:  Daniel Shepshelovich; Ariadna Tibau; Consolación Molto; Hadar Goldvaser; Alberto Ocana; Bostjan Šeruga; Eitan Amir
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

2.  Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial.

Authors:  S Magnan; J E Tota; M El-Zein; A N Burchell; J T Schiller; A Ferenczy; P-P Tellier; F Coutlée; E L Franco
Journal:  Clin Microbiol Infect       Date:  2018-04-21       Impact factor: 8.067

Review 3.  Clinical trial publications.

Authors:  Sarah Cuschieri
Journal:  Saudi J Anaesth       Date:  2019-04

4.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.